Serum drug concentrations predictive of pulmonary tuberculosis outcomes

Journal of Infectious Diseases

Volumn 208, Issue 9, 2013, Pages 1464-1473

  Pasipanodya, Jotam G ^a   McIlleron, Helen ^b   Burger, André ^c   Wash, Peter A ^c   Smith, Peter ^c   Gumbo, Tawanda ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c Brewelskloof Hospital   (South Africa)

Author keywords

classification and regression tree analysis; drug concentrations; hollow fiber system; nonlinear systems; outcomes; pharmacokinetic variability; tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; ISONIAZID PLUS RIFAMPICIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLASSIFICATION AND REGRESSION TREE ANALYSIS; DECISION TREE; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG TREATMENT FAILURE; FEMALE; HEMOPTYSIS; HUMAN; LONG TERM CARE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PREDICTIVE VALUE; PRIORITY JOURNAL; RELAPSE; RETREATMENT; RISK; SENSITIVITY AND SPECIFICITY; SPUTUM EXAMINATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT REFUSAL;

CLASSIFICATION AND REGRESSION TREE ANALYSIS; DRUG CONCENTRATIONS; HOLLOW-FIBER SYSTEM; NONLINEAR SYSTEMS; OUTCOMES; PHARMACOKINETIC VARIABILITY; TUBERCULOSIS;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; AREA UNDER CURVE; FEMALE; HUMANS; ISONIAZID; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PROSPECTIVE STUDIES; PYRAZINAMIDE; RIFAMPIN; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84885395522     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit352     Document Type: Article

References (50)

1. Visser ME, Grewal HM, Swart EC, et al. The effect of vitamin A and zinc supplementation on treatment outcomes in pulmonary tuberculosis: A randomized controlled trial. Am J Clin Nutr 2011; 93:93-100
2. MacKenzie WR, Heilig CM, Bozeman L, et al. Geographic differences in time to culture conversion in liquid media: Tuberculosis trials consortium study 28. Culture conversion is delayed in Africa. PLoS One 2011; 6:e18358
3. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362:697-706
4. Calver AD, Falmer AA, Murray M, et al. Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa. Emerg Infect Dis 2010; 16:264-71
5. Gumbo T, Louie A, Deziel MR, et al. Concentration-Dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin. Antimicrob Agents Chemother 2007; 51:3781-8
6. Gumbo T, Louie A, Liu W, et al. Isoniazid bactericidal activity and resistance emergence: Integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob Agents Chemother 2007; 51:2329-36
7. Gumbo T, Siyambalapitiyage Dona CS, Meek C, Leff R. Pharmacokinetics- pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: A paradigm for faster assessment of new antituberculosis drugs. Antimicrob Agents Chemother 2009; 53:3197-204
8. Srivastava S, Pasipanodya JG, Meek C, Leff R, Gumbo T. Multidrugresistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis 2011; 204:1951-9
9. Pasipanodya JG, Gumbo T. A meta-Analysis of self-Administered versus directly observed therapy effect on microbiologic failure, relapse, and acquired drug resistance in tuberculosis patients. Clin Infect Dis 2013; 57:21-31
10. Chideya S, Winston CA, Peloquin CA, et al. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among a predominantly HIV-infected cohort of adults with tuberculosis from Botswana. Clin Infect Dis 2009; 48:1685-94
11. Narita M, Hisada M, Thimmappa B, et al. Tuberculosis recurrence: Multivariate analysis of serum levels of tuberculosis drugs, human immunodeficiency virus status, and other risk factors. Clin Infect Dis 2001; 32:515-7
12. Chang KC, Leung CC, Yew WW, et al. Peak plasma rifampicin level in tuberculosis patients with slow culture conversion. Eur J Clin Microbiol Infect Dis 2008; 27:467-72
13. Weiner M, Benator D, Burman W, et al. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. Clin Infect Dis 2005; 40:1481-91
14. Heysell SK, Moore JL, Keller SJ, Houpt ER. Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA. Emerg Infect Dis 2010; 16:1546-53
15. Kimerling ME, Phillips P, Patterson P, Hall M, Robinson CA, Dunlap NE. Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients. Chest 1998; 113:1178-83
16. Mehta JB, Shantaveerapa H, Byrd RP Jr., Morton SE, Fountain F, Roy TM. Utility of rifampin blood levels in the treatment and follow-Up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy. Chest 2001; 120:1520-4
17. Srivastava S, Musuka S, Sherman C, Meek C, Leff R, Gumbo T. Efflux-pump-Derived multiple drug resistance to ethambutol monotherapy in Mycobacterium tuberculosis and the pharmacokinetics and pharmacodynamics of ethambutol. J Infect Dis 2010; 201: 1225-31
18. Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 2002; 62:2169-83
19. Hall RG, Swancutt MA, Meek C, Leff RD, Gumbo T. Ethambutol pharmacokinetic variability is linked to body mass in overweight, obese, and extremely obese people. Antimicrob Agents Chemother 2012; 56:1502-7
20. Mandelbrot BB. The fractal geometry of nature. New York: W.H. Freeman and Company, 1982
21. Campbell D, Farmer D, Crutchfield J, Jen E. Experimental mathematics: The role of computation in nonlinear science. 28 edn. New York, NY: Association for Computing Machinery, 1985:374-84
22. Coffey DS. Self-organization, complexity and chaos: The new biology for medicine. Nat Med 1998; 4:882-5
23. Dokoumetzidis A, Iliadis A, Macheras P. Nonlinear dynamics in clinical pharmacology: The paradigm of cortisol secretion and suppression. Br J Clin Pharmacol 2002; 54:21-9
24. Jain MK, Pasipanodya JG, Alder L, Lee WM, Gumbo T. Pegylated interferon fractal pharmacokinetics: Individualized dosing for hepatitis C virus infection. Antimicrob Agents Chemother 2012; 57:1115-20
25. Andes D, Ambrose PG, Hammel JP, et al. Use of pharmacokineticpharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia. Antimicrob Agents Chemother 2011; 55:2113-21
26. Breiman L, Friedman J, Stone CJ, Olshen RA. Classification and regression trees. Boca Raton: Chapman and Hall/CRC, 1984
27. Steinberg D, Colla P. CART: Tree-structured non-parametric data analysis. San Diego: Salford Systems, 1995
28. Kim H, Loh WY. Classification trees with unbiased multiway splits. J Am Stat Assoc 2001; 88:457-67
29. World Health Organization, International Union Against Tuberculosis and Lung Disease, Royal Netherlands Tuberculosis Association. Revised international definitions in tuberculosis control. Int J Tuberc Lung Dis 2001; 5:213-5
30. McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother 2006; 50:1170-7
31. McIlleron H, Wash P, Burger A, Folb P, Smith P. Widespread distribution of a single drug rifampicin formulation of inferior bioavailability in South Africa. Int J Tuberc Lung Dis 2002; 6:356-61
32. ADAPT 5 User's Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software. [computer program]. Los Angeles: Biomedical Simulations Resource, 2009
33. Drusano GL, Forrest A, Yuen G, Plaisance K, Leslie J. Optimal sampling theory: Effect of error in a nominal parameter value on bias and precision of parameter estimation. J Clin Pharmacol 1994; 34:967-74
34. Wilkins JJ, Langdon G, McIlleron H, Pillai GC, Smith PJ, Simonsson US. Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients. Eur J Clin Pharmacol 2006; 62:727-35
35. Chigutsa E, Visser ME, Swart EC, et al. The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: Dosing implications. Antimicrob Agents Chemother 2011; 55:4122-7
36. Wilkins JJ, Langdon G, McIlleron H, Pillai GC, Smith PJ, Simonsson US. Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients. Br J Clin Pharmacol 2011; 72:51-62
37. Breiman L. Technical note: Some properties of splitting criteria. Machine Learning 1996; 24:41-7
38. Lewis RJ. An introduction to classification and regression tree (CART) analysis. In: 2000 Annual Meeting of the Society for Academic Emergency Medicine (San Francisco). Des Plaines, IL: Society for Academic Emergency Medicine, 2000. http://www.srnr.arizona.edu/rnr/rnr573/ Readings/lewis1.pdf. Accessed 7 April 2013
39. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167:603-62
40. Milán Segovia RC, Domínguez Ramírez AM, Jung Cook H, et al. Population pharmacokinetics of rifampicin in Mexican patients with tuberculosis. J Clin Pharm Ther 2013; 38:56-61
41. Zhu M, Starke JR, Burman WJ, et al. Population pharmacokinetic modeling of pyrazinamide in children and adults with tuberculosis. Pharmacotherapy 2002; 22:686-95
42. Thee S, Seddon JA, Donald PR, et al. Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: Evidence for implementation of revised World Health Organization recommendations. Antimicrob Agents Chemother 2011; 55:5560-7
43. Jindani A, Dore CJ, Mitchison DA. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med 2003; 167:1348-54
44. Mitchison DA. Basic mechanisms of chemotherapy. Chest 1979; 76(6 Suppl):771-81
45. Almeida D, Nuermberger E, Tasneen R, et al. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis. Antimicrob Agents Chemother 2009; 53:4178-84
46. Schmalstieg AM, Srivastava S, Belkaya S, et al. The antibiotic resistance arrow of time: Efflux pump induction is a general first step in the evolution of mycobacterial drug resistance. Antimicrob Agents Chemother 2012; 56:4806-15
47. Gumbo T. New susceptibility breakpoints for first-line antituberculosis drugs based on antimicrobial pharmacokinetic/pharmacodynamic science and population pharmacokinetic variability. Antimicrob Agents Chemother 2010; 54:1484-91
48. Ahmad Z, Peloquin CA, Minkowski A, Grosset JH, Nuermberger EL, Ahmad Parry Z. The anti-Tuberculous activity of pyrazinamide is driven by AUC/MIC in murine tuberculosis [O-01]. In program and abstracts of the 3rd International Workshop on Clinical Pharmacology of Tuberculosis Drugs. Boston, MA, 2010: 3
49. Salfinger M, Heifets LB. Determination of pyrazinamide MICs for Mycobacterium tuberculosis at different pHs by the radiometric method. Antimicrob Agents Chemother 1988; 32:1002-4
50. Conte JE Jr., Golden JA, Duncan S, McKenna E, Zurlinden E. Intrapulmonary concentrations of pyrazinamide. Antimicrob Agents Chemother 1999; 43:1329-33